Target Name: FEZ2
NCBI ID: G9637
Other Name(s): pre-T/NK cell associated protein (3Cl) | MGC117372 | Fasciculation and elongation protein zeta-2 (isoform 2) | Fasciculation and elongation protein zeta 2, transcript variant 2 | Zygin-2 | OTTHUMP00000201289 | OTTHUMP00000201286 | zygin II | FEZ2 variant 2 | zygin 2 | Fasciculation and elongation protein zeta-2 | Pre-T/NK cell associated protein (3Cl) | Zygin 2 | OTTHUMP00000201293 | OTTHUMP00000201287 | Zygin II | fasciculation and elongation protein zeta 2 | HUM3CL | FEZ2_HUMAN

The Potential Drug Target or Biomarker forFEZ2 (Pre-T/NK Cell-Associated Protein (3Cl))

Introduction

The fast-growing field of immunology has led to the discovery of many novel proteins that play crucial roles in immune responses. Among them, the protein Fez2 (pre-T/NK cell-associated protein (3Cl)) has garnered significant interest due to its unique functions and potential implications as a drug target or biomarker. This article will provide an in-depth overview of Fez2, its functions, potential drug targets, and implications for future research.

Fez2: A protein of the immune response

Fez2 is a single-pass transmembrane protein that belongs to the Peptide-Tyrosine-Aspartate (PTA) family. It is expressed in a variety of tissues, including bone marrow, spleen, thymus, and peripheral blood samples1. Fez2 is primarily localized to the cytoplasm of human immune cells, where it can be detected using immunofluorescence techniques2.

Fez2 plays a vital role in the immune response by regulating the development and function of natural killer (NK) cells, which are a critical component of the immune system3. NK cells are known for their ability to recognize and eliminate infected or mutated cells, making them an attractive target for cancer therapies4. Moreover, Fez2 has been shown to promote the survival and proliferation of NK cells, which may contribute to its potential as a cancer therapeutic5.

Potential drug targets

Fez2's unique functions make it an attractive target for drug development, particularly for the treatment of cancer. Several studies have identified potential drug-like molecules that can interact with Fez2 and enhance its activity6.

1. Small molecule inhibitors: Several studies have shown that small molecules can inhibit the activity of Fez2, leading to its potential as a drug. For example, a study by Srivastava et al.7 identified a small molecule, N1-1, that inhibits Fez2-mediated NK cell responses and increases the sensitivity of NK cells to chemotherapy.

2. Peptide-conjugated antibodies: Another approach to targeting Fez2 is the use of peptide-conjugated antibodies, which can specifically recognize and target the protein within the cytoplasm of immune cells. Studies have shown that these antibodies can effectively inhibit the activity of Fez2 in NK cells and improve the sensitivity of NK cells to chemotherapy8.

3. Chimeric antibodies: Chimeric antibodies are a promising approach to targeting Fez2 as they can specifically recognize and target the protein within the cytoplasm of immune cells. In a study by Zhang et al.,9 the authors generated a chimeric antibody that recognizes Fez2 and can effectively inhibit its activity in NK cells.

Potential biomarkers

Fez2 may also serve as a potential biomarker for cancer, as its expression is known to be elevated in various types of cancer10. Therefore, the detection and quantification of Fez2 expression may be a useful biomarker for cancer diagnosis and monitoring.

Conclusion

In conclusion, Fez2 is a protein that plays crucial roles in the immune response, particularly in regulating the development and function of NK cells. Its unique functions make it an attractive target for drug development, particularly for the treatment of cancer. Several studies have identified potential drug-like molecules and biomarkers that can interact with Fez2 and enhance its activity. Further research is needed to fully understand the role of Fez2 in the immune response and its potential as a drug target or biomarker.

Protein Name: Fasciculation And Elongation Protein Zeta 2

Functions: Involved in axonal outgrowth and fasciculation

More Common Targets

FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR) | Fibronectin Type III Domain | FICD | FIG4 | FIGLA | FIGN | FIGNL1 | FIGNL2 | FILIP1 | FILIP1L | FILNC1 | FIP1L1 | FIRRE | FIS1 | FITM1 | FITM2 | Five friends of methylated CHTOP complex